DexCom (DXCM) vs Zimmer Biomet (ZBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
DexCom (DXCM) has outperformed Zimmer Biomet (ZBH) over the past year, gaining 24.5% versus a loss of 9.6%. Over five years, ZBH leads with a -37.5% price change compared with -38.0% for DXCM. DexCom is the larger company by market cap ($31.63 billion vs $16.97 billion), about 1.9 times the size.
On valuation, Zimmer Biomet trades at a lower forward P/E (9.8x vs 26.8x for DexCom). Zimmer Biomet pays a dividend yielding 1.08%, while DexCom does not currently pay one. DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 8.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | ZBH |
|---|---|---|
| Share price | $83.83 | $89.00 |
| Market cap | $31.63B | $16.97B |
| 1-day change | -0.69% | +0.13% |
| YTD return | +27.18% | -1.16% |
| 1-year return | +24.54% | -9.64% |
| 5-year return | -37.99% | -37.45% |
| P/E ratio (TTM) | 33.26 | 21.60 |
| Forward P/E | 26.81 | 9.81 |
| EPS (TTM) | $2.52 | $4.12 |
| Dividend yield | 0.00% | 1.08% |
| Annual dividend | $0.00 | $0.96 |
| Revenue (latest FY) | $4.66B | $8.23B |
| Revenue growth (YoY) | +15.60% | +7.20% |
| Net income (latest FY) | $836.30M | $705.10M |
| Gross margin | 60.10% | 69.71% |
| Operating margin | 19.56% | 13.34% |
| Net margin | 17.94% | 8.57% |
| 52-week high | $92.59 | $106.88 |
| 52-week low | $54.11 | $79.12 |
| Distance from 52-week high | -9.47% | -16.73% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.80% | +20.49% |
| Average volume | 4.43M | 2.17M |
| Shares outstanding | 377.36M | 190.74M |
| Employees | 11,000 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXCM has outperformed ZBH by 34.2 percentage points over the past year.
- DexCom trades at a higher earnings multiple (33.3x vs 21.6x trailing P/E).
- Zimmer Biomet offers a meaningfully higher dividend yield (1.08% vs 0.00%).
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 8.6 cents for Zimmer Biomet.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +7.20%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About Zimmer Biomet
ZBH stock →Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Health Care · Industrial Specialties · 17,000 employees
DXCM vs ZBH FAQ
Which is bigger, DexCom or Zimmer Biomet?
DexCom (DXCM) is larger, with a market capitalization of $31.63B compared with $16.97B for Zimmer Biomet (ZBH).
Which stock has performed better over the past year, DXCM or ZBH?
DXCM returned +24.54% over the past 12 months, compared with -9.64% for ZBH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or ZBH?
ZBH has the lower trailing P/E at 21.6, versus 33.3 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, DexCom or Zimmer Biomet?
Zimmer Biomet pays a dividend yielding 1.08%, while DexCom does not currently pay a regular dividend.
Are DexCom and Zimmer Biomet in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for DexCom and Industrial Specialties for Zimmer Biomet.